# Tissue Bank

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tissue-bank

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.catb.org.cn
- Latest round: Series D (Nov 26, 2018)
- Investors on record: 5

## About

Established in 2011 and based in Shanghai, China, Tissue Bank is a biotechnology company mainly engaged in the development of transplantation immunotherapy technology. The branches have been set up in Shenzhen and Xi'an. In December 2018, it closed a series D funding. In 2023, the reproductive immunity and general examination business was started. The Chairman of the board and Founder, Zhongzheng Zheng, graduated from Xiamen University, and he is a member of Civil Construction.

The company is committed to the fields of immunology, including scientific research, tissue storage, immunotherapy evaluation, and diagnostic reagents. It provides testing services for various types of diseases mediated by immunity such as clinical blood and body fluid testing, clinical cell molecular genetics testing, etc. It has built a series of high-throughput sequencing platforms including HiSeq X Ten, NextSeq 500, MiSeq, and so on.

## Funding rounds

- Series D, Nov 26, 2018 — Shanghai Fengbai Enterprise Management, Shanghai Deguan Asset Management
- Series B, Jul 15, 2016 — Apricot Capital
- Series A, Mar 5, 2015 — Tianfeng Capital
- Angel, Mar 1, 2013 — Tsing-Yuan Capital

## Investors

- Tsing-Yuan Capital (https://capitalatlas.ai/funds/tsing-yuan-capital) — Angel
- Tianfeng Capital (https://capitalatlas.ai/funds/tianfeng-capital) — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series B
- Shanghai Fengbai Enterprise Management — Series D
- Shanghai Deguan Asset Management (https://capitalatlas.ai/funds/shanghai-deguan-asset-management) — Series D